摘要
急性髓系白血病(acute myeloid leukemia,AML)是一种高度异质性的恶性血液病,近些年随着化疗、靶向药物和造血干细胞移植的发展,AML患者的疗效已有较大的提高,但总体而言,绝大部分患者仍无法治愈。目前,成人AML患者5年生存率仍未超过30%。嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在复发难治性B淋巴细胞肿瘤领域取得了显著疗效,越来越多的研究开始研发CAR-T疗法在其他类型肿瘤及疾病中的应用。本文主要就近些年CAR-T疗法在AML中的临床应用和研究进展做出综述。
Acute myeloid leukemia(AML)is a highly heterogeneous hematologic malignancy.In recent years,with the development of chemotherapy,targeted drugs,and hematopoietic stem cell transplantation,the efficacy of treatment for patients with AML has greatly improved;however,most patients remain incurable.The 5-year survival rate of adult patients with AML remains<30%.The efficacy of chimeric antigen receptor(CAR)T-cell therapy for relapsed and refractory B-lymphocyte tumors has been significant,and an increasing number of studies have begun developing the application of CAR T-cell therapy for other types of tumors and diseases.This study reviews the clinical application and research progress of CAR T-cell therapy for AML in recent years.
作者
肖植文
喻敏
李菲
Zhiwen Xiao;Min Yu;Fei Li(Department of Hematology,The First Affiliated Hospital of Nanchang University,Institute of Hematology,Jiangxi Academy of Clinical Medical Sciences,Institute of Lymphatic Tumor Diseases of Nanchang University,Nanchang 330006,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2022年第20期1052-1055,共4页
Chinese Journal of Clinical Oncology
基金
江西省自然科学基金重点项目(编号:20192ACB20030)
江西省科技创新基地计划(江西省血液病临床医学研究中心)项目(编号:20212BCG74001)
中央引导地方科技发展专项-国家血液系统疾病临床医学研究中心江西分中心项目(编号:20111ZDG02006)资助。
关键词
嵌合抗原受体
T
细胞
急性髓系白血病
靶向治疗
不良事件
chimeric antigen receptor T-cell(CAR-T)
acute myeloid leukemia(AML)
targeted therapy
adverse event